These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38944421)

  • 1. Expression of PD-L1 Is Increased by Methionine Restriction Using Recombinant Methioninase in Human Colorectal Cancer Cells.
    Mizuta K; Kang BM; Han Q; Kubota Y; Morinaga S; Sato M; Bouvet M; Tome Y; Nishida K; Hoffman RM
    Cancer Genomics Proteomics; 2024; 21(4):395-398. PubMed ID: 38944421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective Synergy of Rapamycin Combined With Methioninase on Cancer Cells Compared to Normal Cells.
    Ardjmand D; Kubota Y; Sato M; Han Q; Mizuta K; Morinaga S; Hoffman RM
    Anticancer Res; 2024 Mar; 44(3):929-933. PubMed ID: 38423628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant Methioninase Decreased the Effective Dose of Irinotecan by 15-fold Against Colon Cancer Cells: A Strategy for Effective Low-toxicity Treatment of Colon Cancer.
    Sato M; Han Q; Kubota Y; Baranov A; Ardjmand D; Mizuta K; Morinaga S; Kang BM; Kobayashi N; Bouvet M; Ichikawa Y; Nakajima A; Hoffman RM
    Anticancer Res; 2024 Jan; 44(1):31-35. PubMed ID: 38159986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergy of Rapamycin and Methioninase on Colorectal Cancer Cells Requires Simultaneous and Not Sequential Administration: Implications for mTOR Inhibition.
    Ardjmand D; Sato M; Han Q; Kubota Y; Mizuta K; Morinaga S; Hoffman RM
    Cancer Diagn Progn; 2024; 4(4):396-401. PubMed ID: 38962555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer.
    Kawaguchi K; Miyake K; Han Q; Li S; Tan Y; Igarashi K; Lwin TM; Higuchi T; Kiyuna T; Miyake M; Oshiro H; Bouvet M; Unno M; Hoffman RM
    Cell Cycle; 2018; 17(7):868-873. PubMed ID: 29623758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant Methioninase Increases Eribulin Efficacy 16-fold in Highly Eribulin-resistant HT1080 Fibrosarcoma Cells, Demonstrating Potential to Overcome the Clinical Challenge of Drug-resistant Soft-tissue Sarcoma.
    Morinaga S; Han Q; Mizuta K; Kang BM; Sato M; Bouvet M; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Higuchi T; Tsuchiya H; Demura S; Hoffman RM
    Anticancer Res; 2024 Sep; 44(9):3777-3783. PubMed ID: 39197933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term Stable Disease in a Rectal-cancer Patient Treated by Methionine Restriction With Oral Recombinant Methioninase and a Low-methionine Diet.
    Kubota Y; Han Q; Hamada K; Aoki Y; Masaki N; Obara K; Tsunoda T; Hoffman RM
    Anticancer Res; 2022 Aug; 42(8):3857-3861. PubMed ID: 35896248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of recombinant methioninase in combination with cisplatin on human colon tumors in nude mice.
    Tan Y; Sun X; Xu M; Tan X; Sasson A; Rashidi B; Han Q; Tan X; Wang X; An Z; Sun FX; Hoffman RM
    Clin Cancer Res; 1999 Aug; 5(8):2157-63. PubMed ID: 10473100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methioninase gene therapy of human cancer cells is synergistic with recombinant methioninase treatment.
    Miki K; Al-Refaie W; Xu M; Jiang P; Tan Y; Bouvet M; Zhao M; Gupta A; Chishima T; Shimada H; Makuuchi M; Moossa AR; Hoffman RM
    Cancer Res; 2000 May; 60(10):2696-702. PubMed ID: 10825143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Broad selective efficacy of recombinant methioninase and polyethylene glycol-modified recombinant methioninase on cancer cells In Vitro.
    Tan Y; Xu M; Hoffman RM
    Anticancer Res; 2010 Apr; 30(4):1041-6. PubMed ID: 20530407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergy of oral recombinant methioninase (rMETase) and 5-fluorouracil on poorly differentiated gastric cancer.
    Miyake M; Miyake K; Han Q; Igarashi K; Kawaguchi K; Barangi M; Kiyuna T; Sugisawa N; Higuchi T; Oshiro H; Zhang Z; Razmjooei S; Bouvet M; Endo I; Hoffman RM
    Biochem Biophys Res Commun; 2023 Feb; 643():48-54. PubMed ID: 36586158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral Installation of Recombinant Methioninase-producing
    Kubota Y; Han Q; Hamada K; Aoki Y; Masaki N; Obara K; Baranov A; Bouvet M; Tsunoda T; Hoffman RM
    Cancer Genomics Proteomics; 2022; 19(6):683-691. PubMed ID: 36316039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming High Trabectedin Resistance of Soft-tissue Sarcoma With Recombinant Methioninase: A Potential Solution of a Recalcitrant Clinical Problem.
    Morinaga S; Han Q; Mizuta K; Kang BM; Sato M; Bouvet M; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Higuchi T; Tsuchiya H; Demura S; Hoffman RM
    Anticancer Res; 2024 Sep; 44(9):3785-3791. PubMed ID: 39197928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective Metabolic Targeting of Human Osteosarcoma Cells
    Igarashi K; Kawaguchi K; Kiyuna T; Miyake K; Murakami T; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Hoffman RM
    Anticancer Res; 2017 Sep; 37(9):4807-4812. PubMed ID: 28870899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model.
    Murakami T; Li S; Han Q; Tan Y; Kiyuna T; Igarashi K; Kawaguchi K; Hwang HK; Miyake K; Singh AS; Nelson SD; Dry SM; Li Y; Hiroshima Y; Lwin TM; DeLong JC; Chishima T; Tanaka K; Bouvet M; Endo I; Eilber FC; Hoffman RM
    Oncotarget; 2017 May; 8(22):35630-35638. PubMed ID: 28404944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deletion of
    Aoki Y; Tome Y; Han Q; Yamamoto J; Hamada K; Masaki N; Kubota Y; Bouvet M; Nishida K; Hoffman RM
    Cancer Genomics Proteomics; 2022; 19(3):299-304. PubMed ID: 35430564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant Methioninase Lowers the Effective Dose of Regorafenib Against Colon-Cancer Cells: A Strategy for Widespread Clinical Use of a Toxic Drug.
    Choobin BB; Kubota Y; Han Q; Ardjmand D; Morinaga S; Mizuta K; Bouvet M; Tsunoda T; Hoffman RM
    Cancer Diagn Progn; 2023; 3(6):655-659. PubMed ID: 37927805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant Oral Methioninase (o-rMETase) Combined With Oxaliplatinum Plus 5-Fluorouracil Improves Survival of Mice With Massive Colon-Cancer Peritoneal Carcinomatosis.
    Kim MJ; Han Q; Bouvet M; Hoffman RM; Park JH
    Anticancer Res; 2023 Jan; 43(1):19-24. PubMed ID: 36585181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA-Binding Agent Trabectedin Combined With Recombinant Methioninase Is Synergistic to Decrease Fibrosarcoma Cell Viability and Induce Nuclear Fragmentation But Not Synergistic on Normal Fibroblasts.
    Morinaga S; Han Q; Kubota Y; Mizuta K; Kang BM; Sato M; Bouvet M; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Higuchi T; Tsuchiya H; Demura S; Hoffman RM
    Anticancer Res; 2024 Jun; 44(6):2359-2367. PubMed ID: 38821601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant Methioninase Is Selectively Synergistic With Doxorubicin Against Wild-type Fibrosarcoma Cells Compared to Normal Cells and Overcomes Highly-Doxorubicin-resistant Fibrosarcoma.
    Morinaga S; Han Q; Mizuta K; Kang BM; Sato M; Bouvet M; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Higuchi T; Tsuchiya H; Demura S; Hoffman RM
    Anticancer Res; 2024 Aug; 44(8):3261-3268. PubMed ID: 39060039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.